Author: Newsdesk

• ELPIS II top-line trial results are anticipated in the third quarter of 2026
• Laromestrocel Biological License Application (BLA) submission for full traditional approval for HLHS anticipated if ELPIS II results are positive
• U.S. FDA has awarded laromestrocel HLHS program Rare Pediatric Disease designation, Orphan Drug designation, and Fast Track designation
• Laromestrocel HLHS program has the potential to address an unmet medical need with significant U.S. market opportunities
• Even with current standard of care surgeries, only 50% of infants survive to adolescence due to right ventricular failure
  

MIAMI, Jan. 26, 2026 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted Longeveron a Type C meeting at the end of March to prepare for the anticipated third quarter data readout of ELPIS II, the pivotal Phase 2 clinical trial evaluating the Company’s proprietary stem cell therapy, laromestrocel (LOMECEL-B®), as a potential treatment for Hypoplastic Left Heart Syndrome (HLHS), a rare pediatric and orphan-designated disease. The primary purpose of the meeting is to gain alignment on the clinical efficacy data endpoints and statistical analysis plan (SAP) to support a Biologics Licensing Application (BLA).

The Company expects to provide a regulatory update after the receipt of the official meeting minutes.

ELPIS II is a Phase 2b clinical trial evaluating laromestrocel as a potential adjunct therapy for HLHS. The clinical trial enrolled 40 pediatric patients at twelve premiere infant and children’s treatment institutions across the country. ELPIS II is being conducted in collaboration with the National Heart, Lung, and Blood Institute (NHLBI) through grants from the National Institutes of Health (NIH).

About Hypoplastic Left Heart Syndrome (HLHS)

HLHS is a congenital birth defect in which the left ventricle (one of the pumping chambers of the heart) is either severely underdeveloped or missing. As a consequence, infants born with this condition have severely diminished systemic blood flow, which requires them to undergo a complex, three stage heart reconstruction surgery process over the course of the first 5 years of their lives. Although surgical advances have enabled survival into adulthood for some patients, early mortality remains substantial in this population, due to right ventricular failure. As such, there remains an important unmet medical need to improve right ventricular function in these patients in order to support both short-term and long-term outcomes.

About Longeveron Inc.

Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is laromestrocel (LOMECEL-B®), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Laromestrocel has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease (AD), and Pediatric Dilated Cardiomyopathy (DCM). Laromestrocel development programs have received five distinct and important FDA designations: for the HLHS program – Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program – Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.

Forward-Looking Statements

Certain statements in this press release that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which reflect management’s current expectations, assumptions, and estimates of future operations, performance and economic conditions, and involve known and unknown risks, uncertainties, and other important factors that could cause actual results, performance, or achievements to differ materially from those anticipated, expressed, or implied by the statements made herein. Forward-looking statements are generally identifiable by the use of forward-looking terminology such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expects,” “intend,” “looks to,” “may,” “on condition,” “plan,” “potential,” “predict,” “preliminary,” “project,” “see,” “should,” “target,” “will,” “would,” or the negative thereof or comparable terminology, or by discussion of strategy or goals or other future events, circumstances, or effects. Factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statements in this release include, but are not limited to, our cash position and need to raise additional capital, the difficulties we may face in obtaining access to capital, and the dilutive impact it may have on our investors; our financial performance, and ability to continue as a going concern; the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements; the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results; the timing and focus of our ongoing and future preclinical studies and clinical trials, and the reporting of data from those studies and trials; the size of the market opportunity for certain of our product candidates, including our estimates of the number of patients who suffer from the diseases we are targeting; our ability to scale production and commercialize the product candidate for certain indications; the success of competing therapies that are or may become available; the beneficial characteristics, safety, efficacy and therapeutic effects of our product candidates; our ability to obtain and maintain regulatory approval of our product candidates in the U.S. and other jurisdictions; our plans relating to the further development of our product candidates, including additional disease states or indications we may pursue; our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available and our ability to avoid infringing the intellectual property rights of others; the need to hire additional personnel and our ability to attract and retain such personnel; and our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.

Further information relating to factors that may impact the Company’s results and forward-looking statements are disclosed in the Company’s filings with the Securities and Exchange Commission, including Longeveron’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission on February 28, 2025, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. The Company operates in highly competitive and rapidly changing environment; therefore, new factors may arise, and it is not possible for the Company’s management to predict all such factors that may arise nor assess the impact of such factors or the extent to which any individual factor or combination thereof, may cause results to differ materially from those contained in any forward-looking statements. The forward-looking statements contained in this press release are made as of the date of this press release based on information available as of the date of this press release, are inherently uncertain, and the Company disclaims any intention or obligation, other than imposed by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Investor and Media Contact:

Derek Cole
Investor Relations Advisory Solutions
[email protected]

NEW YORK, Jan. 26, 2026 (GLOBE NEWSWIRE) — Blue Gold Limited (Nasdaq: BGL) (“Blue Gold” or the “Company”), a next-generation gold development and technology company, today announced that it has successfully completed the first minting of its genesis Standard Gold Coins (SGC), marking a significant milestone in the operational rollout of its gold-backed digital asset framework.

Each SGC corresponds to one gram of fully allocated physical gold, minted only upon verified custody intake and subject to defined compliance and authorization procedures. The initial minting represents the first issuance of SGC fully backed by allocated physical gold held in professional custody, in accordance with the governance, reserve management, and operational controls outlined in the Company’s recently published Standard Gold Coin White Paper.

“Gold has served as a store of value for thousands of years, but this minting brings it fully into the digital age in a way that preserves true physical ownership, verifiable backing, and the transparency that comes from being developed and operated by a U.S. publicly traded company,” said Andrew Cavaghan, Chief Executive Officer of Blue Gold. “The successful initial minting demonstrates that the infrastructure, custody framework, and operational controls behind SGC are now live and functioning exactly as designed. This milestone moves us from concept to execution and validates the discipline and rigor we have applied to building an institutional-grade digital gold product.”

The initial minting was distributed across 100 individual holders, each acquiring one Standard Gold Coin and collectively representing the first on-chain ownership of SGC backed by fully allocated physical gold.

“What stood out to us was not just that gold was being tokenized, but how it was being done,” said Kris Meyer, of Black Eagle Partners. “The combination of allocated physical gold, verifiable custody, and public-company oversight created a level of trust that we believe is essential for digital gold to succeed at scale.”

“Digital gold only works if trust comes first,” said Max Osbon, of Osbon Capital. “SGC stands out because it treats physical backing, verification, and transparency as prerequisites, not afterthoughts. The controls, custody, and disclosure behind SGC represent a system designed for durability and scale.”

“Credibility is everything when it comes to gold, and SGC treats physical backing, custody, and governance as non-negotiable requirements, not optional features,” said Wesley Paul, former Global Head of Investments, JP Morgan. “The structure is deliberately simple and disciplined, which is exactly what gold ownership should be.”

With the first minting now complete, Blue Gold expects to open SGC to public purchase in the near term. The Company has already generated strong early demand for SGC, including more than one million pre-registration indications of interest recorded within five days of its initial launch announcement in November.

“Gold doesn’t need to change to remain relevant, but how it’s held and utilised does,” Cavaghan added. “SGC is built to meet that need, and this first minting demonstrates that the system is market-ready.”

About Blue Gold Limited

Blue Gold Limited (Nasdaq: BGL) is a next-generation gold development company focused on acquiring and aggregating high-potential mining assets across strategic global jurisdictions. The Company’s mission is to unlock untapped value in the gold sector by combining disciplined resource acquisition with innovative monetization models, including asset-backed digital instruments. Blue Gold is committed to responsible development, operational transparency, and leveraging modern financial technologies to redefine how gold is produced, accessed, and owned in the 21st century.

Blue Gold prioritizes growth, sustainable development, and transparency in all our business practices. We believe that our commitment to responsible mining will enable us to create value for our shareholders while minimizing our environmental footprint.



Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. You are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements include, but are not limited to: general economic or political conditions; negative economic conditions that could impact Blue Gold Limited and the gold industry in general; reduction in demand for Blue Gold Limited’s products; changes in the markets that Blue Gold Limited targets; and any change in laws applicable to Blue Gold Limited or any regulatory or judicial interpretation. As a result, we cannot assure you that the forward-looking statements included in this press release will prove to be accurate or correct. These and other important factors and risks are discussed in Blue Gold Limited’s shell company report on Form 20-F, filed with the U.S. Securities and Exchange Commission (the “SEC”) on July 1, 2025, and other filings with the SEC. In light of these risks, uncertainties, and assumptions, the future performance or events described in the forward-looking statements in this press release might not occur. Accordingly, you should not rely upon forward-looking statements as a prediction of actual results, and we do not assume any responsibility for the accuracy or completeness of any of these forward-looking statements. Except as required by applicable law, we do not undertake any obligation to, and will not, update any forward-looking statements, whether as a result of new information, future events, or otherwise. For more information regarding Blue Gold Limited, please visit https://bluegoldmine.com.

No Offer or Solicitation

This press release shall not constitute a solicitation of a proxy, consent, or authorization with respect to any securities or in respect of the proposed business combination. This press release shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption.

For Further Information Contact:
Dave Gentry
RedChip Companies, Inc.
1-800-REDCHIP (733-2447)
1-407-644-4256
[email protected]

SUNNYVALE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) — Intuitive (NASDAQ: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced that the U.S. Food and Drug Administration (FDA) has cleared the da Vinci 5 system for certain cardiac procedures, including mitral valve repair and IMA (internal mammary artery) mobilization for cardiac revascularization. 
        
Cardiovascular disease remains the leading cause of death worldwide, claiming nearly 18 million lives each year.ⁱ More than two million patients worldwide undergo open heart surgery annuallyⁱⁱ, with most procedures requiring a sternotomy, an approach that involves splitting the breastbone to open the chest and access the heart.

“Opening the chest to perform surgical procedures can involve significant pain, high risk of complications, and long recovery times that can affect patients’ physical and psychological wellbeing,” said Intuitive chief executive officer Dave Rosa. “This clearance reflects our commitment to advancing minimally invasive cardiac surgery so more surgeons and care teams can pursue improved outcomes for their patients.”

Cardiac surgery was the first specialty cleared on the original da Vinci System in 2002. Since then, more than 140,000 robotic-assisted cardiac procedures have been performed using da Vinci systems across 51 countries. While early milestones demonstrated clinical potential, a combination of technical limitations of first‑generation platforms and the absence of a global training and support infrastructure led Intuitive to shift its primary focus away from cardiac surgery. Today, with those barriers addressed and a mature ecosystem in place, minimally invasive cardiac surgery is positioned for meaningful expansion with da Vinci 5.

The design of da Vinci 5 can support minimally invasive cardiac procedures by enabling surgeons to operate through small incisions without opening the breastbone. The system offers:

• 10,000x computing power for future innovation and digital solutions.
• Smart instrumentation capturing 1,000+ data points per second.
• Advanced imaging for enhanced visualization of vessels and perfusion.
• An integrated digital ecosystem supporting the complete journey from pre-operative planning through post-operative analytics.

“Da Vinci 5 marks the beginning of a global initiative to help transform cardiac care,” said Intuitive’s global vice president of cardiac Darla Hutton. “By combining 30 years of meaningful innovation, structured team-based training programs and a service model built on reliability and safety, we believe we can enable cardiac teams to adopt robotic-assisted surgery in a consistent, scalable and sustainable way.”

To support adoption of cardiac surgery with da Vinci 5, Intuitive has established a dedicated team focused on building infrastructure, including the development of bespoke training programs, clinical evidence generation, and cardiac-specific instruments and accessories. A limited number of U.S. sites will begin working with Intuitive through 2026 to establish da Vinci 5 cardiac programs.

Da Vinci 5 is now indicated for the following selected thoracoscopically-assisted cardiac surgical procedures using non-force feedback instruments:

• Mitral valve repair 
• IMA mobilization for cardiac revascularization
• Patent foramen ovale closure
• Atrial septal defect repair
• Left atrial appendage closure/occlusion
• Atrial myxoma excision
• Mitral valve replacement
• Tricuspid valve repair
• Epicardial pacing lead placement

About Intuitive

Intuitive (NASDAQ:ISRG), headquartered in Sunnyvale, California, is a global leader in minimally invasive care and the pioneer of robotic-assisted surgery. Our technologies include the da Vinci surgical system and the Ion endoluminal system. By uniting advanced systems, progressive learning, and value-enhancing services, we help physicians and their teams optimize care delivery to support the best outcomes possible. At Intuitive, we envision a future of care that is less invasive and profoundly better, where disease is identified early and treated quickly, so that patients can get back to what matters most.

About da Vinci Surgical Systems

There are several models of the da Vinci surgical system. The da Vinci surgical systems are designed to help surgeons perform minimally invasive surgery and offer surgeons high-definition 3D vision, a magnified view, and robotic and computer assistance. They use specialized instrumentation, including a miniaturized surgical camera and wristed instruments (i.e., scissors, scalpels, and forceps) that are designed to help with precise dissection and reconstruction deep inside the body.
For more information, please visit the company’s website at www.intuitive.com.

Important Safety Information

For product intended use and/or indications for use, risks, cautions, and warnings and full prescribing information, visit https://manuals.intuitivesurgical.com/market. For summary of the risks associated with surgery refer to www.intuitive.com/safety.

Forward-Looking Statements

This press release contains forward-looking statements which relate to expectations concerning matters that are not historical facts. Statements using words such as “estimates,” “projects,” “believes,” “anticipates,” “plans,” “expects,” “intends,” “may,” “will,” “can,” “could,” “should,” “would,” “targeted,” “potential,” and similar words and expressions are intended to identify forward-looking statements. These forward-looking statements are necessarily estimates reflecting the judgment of Intuitive’s management and involve a number of risks and uncertainties that could cause actual results or impacts on its operations, financial performance, and business position to differ materially from those suggested by the forward-looking statements.

These forward-looking statements include, but are not limited to, statements related to research and development of products and services, manufacturing of products, integration of products, obtaining of regulatory approvals, technical and other performance of products and services, and making products and services available to more patients and health care professionals.

These forward-looking statements should be considered in light of various important factors and involve known and unknown risks, uncertainties, and other factors, which may cause the actual results, performance, or achievements of Intuitive, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements include, among others, economic conditions in the geographic markets in which we operate, changes in governmental regulations, regulatory approval priorities, resources, and timelines, regulatory enforcement priorities, governmental investigations and civil litigation, and other factors discussed in Intuitive’s Annual Reports and other filings with relevant securities regulators.

Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release and which are based on current expectations and are subject to risks, uncertainties, and assumptions that are difficult to predict, including those risk factors identified under the heading “Risk Factors” in Intuitive’s Annual Report on Form 10-K for the year ended December 31, 2024, as updated by its other filings with the U.S. Securities and Exchange Commission. Intuitive’s actual results may differ materially and adversely from those expressed in any forward-looking statements, and it undertakes no obligation to publicly update or release any revisions to these forward-looking statements, except as required by law.

---

ⁱ World Health Organisation (2025), ‘Cardiovascular diseases’. Available at: https://www.who.int/health-topics/cardiovascular-diseases#tab=tab_1
ⁱⁱ National Heart, Lung and Blood Institute (2022). ‘Heart Surgery’. Available at: https://www.nhlbi.nih.gov/health/heart-surgery

Contact Information:

[email protected]
+1 408-523-8181 ext. 6934681

Geneva, Switzerland, Jan. 26, 2026 (GLOBE NEWSWIRE) —

SEALSQ Corp (NASDAQ: LAES) (“SEALSQ” or the “Company”), a global leader in semiconductors, PKI, and post-quantum cryptography (PQC) hardware and software solutions, today announced a live demonstration exploring its Post-Quantum Cryptography Robotic Concept during the Physical AI Roundtable held in Davos on the margins of the World Economic Forum Annual Meeting. The demonstration featured WISeRobot, developed in cooperation with its parent company WISeKey International Holding Ltd (“WISeKey”) (SIX: WIHN, NASDAQ: WKEY), a leading global cybersecurity, blockchain, and IoT company, and illustrated the potential and need for post-quantum security to one day be embedded directly into physical AI and robotic systems.

As quantum computing continues to advance, many of today’s cryptographic standards are expected to become vulnerable. SEALSQ is proactively addressing this challenge by working on the integration of quantum-resistant algorithms and hardware-based roots of trust into robotic platforms, with the goal of ensuring long-term security, integrity, and trusted operation for AI-driven and autonomous systems deployed in real-world, often adversarial environments.

The demonstration leveraged WISeRobot.ch, an advanced robotics platform meant to illustrate how post-quantum security could eventually be anchored across the silicon, firmware, and system levels. During the roundtable, WISeRobot actively participated as a live, interactive presence, animating discussions by demonstrating secure digital identity, trusted human–machine and machine-to-machine interactions, cryptographically protected communications, and hardware-anchored trust in real time.

Physical AI, which is AI embodied in machines that perceive, decide, and act in the physical world, requires a fundamentally different security model than purely digital systems. SEALSQ is exploring and plans to address this by embedding trust directly into its secure semiconductors through hardware-based roots of trust, post-quantum cryptographic accelerators, secure key storage, and lifecycle management. Each Physical AI system could be provisioned at manufacturing with a unique, unclonable cryptographic identity protected inside secure hardware, enabling trusted boot, authenticated firmware and AI models, integrity attestation, and secure interaction with humans, infrastructure, and other machines.

By planning to integrate post-quantum cryptography directly into the semiconductor layer, SEALSQ aims to ensure that communications, commands, AI decisions, and software updates remain secure and authentic even in the presence of future quantum computers. This approach is intended to enable long-lived autonomous systems deployed today to remain resilient well beyond the expected arrival of practical quantum computing capabilities. During the Physical AI Roundtable, David Shrier, Professor of Practice at Imperial College London, described how artificial intelligence and quantum computing are set to converge, fundamentally reshaping how machines learn, reason, and optimize decisions. He emphasized that while quantum technologies will dramatically accelerate certain classes of computation, they will also amplify systemic risk unless AI systems, particularly Physical AI, are built on verifiable trust, secure identity, and resilient cryptographic foundations from the outset.

The human dimension of this transformation was further highlighted by Sol Rashidi, the world’s first Chief AI Officer, former Amazon and C-suite executive, best-selling author, and globally recognized AI anthropologist and workforce architect. Rashidi stressed that as AI expands into Physical AI, where machines interact directly with humans and the real world, human-centric requirements become non-negotiable. She underscored the need for AI systems to be transparent, accountable, explainable, and aligned with human values, noting that without embedded trust, security, and ethical guardrails, Physical AI risks eroding confidence rather than augmenting human capability.

During the same discussions, Mark Hughes, Global Managing Partner of Cybersecurity Services at IBM, stated that quantum computers are expected to arrive as early as 2028 and confirmed that IBM is already prepared for this transition. These perspectives reinforced a shared conclusion among participants: the post-quantum era is approaching faster than previously anticipated, making immediate action essential to protect digital identities, AI systems, and autonomous machines from future cryptographic disruption.

The WISeRobot concept demonstrated at Davos illustrated how post-quantum-ready security can move from theory into operational reality, establishing a new benchmark for trusted autonomous systems in critical environments such as government, healthcare, smart infrastructure, and industrial automation. The demonstration highlighted how intelligent machines can be engineered to be secure by default, resilient by design, and fundamenally aligned with human-centric values.

“Robotics and AI are rapidly becoming part of our critical infrastructure,” said Carlos Moreira, CEO of SEALSQ. “By conducting experiments with post-quantum cryptography in robotics and bringing this first concept to animate our Davos Roundtable, we are demonstrating how trust, security, and human-centric principles can be embedded into intelligent machines from the very beginning.

Jonathan Llamas, VP of Decentralized Strategy of WISeKey noted, “Building on this trusted hardware and post-quantum foundation, SEALCOIN extends the Physical AI stack by enabling a native settlement and accountability layer for autonomous machines. As Physical AI systems move from perception and decision-making to action in real-world environments, true autonomy requires the ability to settle value, enforce economic rules, and execute obligations without human intervention. SEALCOIN provides this missing layer, allowing certified machines to transact, compensate, and be economically accountable in a secure and auditable way. From a machine perspective, integrating settlement is the final step toward autonomy, enabling Physical AI systems not only to act securely, but to operate as independent economic agents within trusted human-defined boundaries.”

SEALSQ’s post-quantum robotics initiative reflects the Company’s broader commitment to developing and delivering quantum-ready technologies that protect digital identities, AI systems, and critical infrastructures worldwide, while contributing to global discussions on trusted artificial intelligence, technological sovereignty, and secure digital ecosystems in a quantum-enabled future.

About SEALSQ:

SEALSQ is a leading innovator in Post-Quantum Technology hardware and software solutions. Our technology seamlessly integrates Semiconductors, PKI (Public Key Infrastructure), and Provisioning Services, with a strategic emphasis on developing state-of-the-art Quantum Resistant Cryptography and Semiconductors designed to address the urgent security challenges posed by quantum computing. As quantum computers advance, traditional cryptographic methods like RSA and Elliptic Curve Cryptography (ECC) are increasingly vulnerable.

SEALSQ is pioneering the development of Post-Quantum Semiconductors that provide robust, future-proof protection for sensitive data across a wide range of applications, including Multi-Factor Authentication tokens, Smart Energy, Medical and Healthcare Systems, Defense, IT Network Infrastructure, Automotive, and Industrial Automation and Control Systems. By embedding Post-Quantum Cryptography into our semiconductor solutions, SEALSQ ensures that organizations stay protected against quantum threats. Our products are engineered to safeguard critical systems, enhancing resilience and security across diverse industries.

For more information on our Post-Quantum Semiconductors and security solutions, please visit www.sealsq.com.

Forward-Looking Statements

This communication expressly or implicitly contains certain forward-looking statements concerning SEALSQ Corp and its businesses. Forward-looking statements include statements regarding our business strategy, financial performance, results of operations, market data, events or developments that we expect or anticipate will occur in the future, as well as any other statements which are not historical facts. Although we believe that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates which are inherently subject to significant uncertainties and contingencies, many of which are beyond our control. Actual results may differ materially from those expressed or implied by such forward-looking statements. Important factors that, in our view, could cause actual results to differ materially from those discussed in the forward-looking statements include SEALSQ’s ability to continue beneficial transactions with material parties, including a limited number of significant customers; market demand and semiconductor industry conditions; and the risks discussed in SEALSQ’s filings with the SEC. Risks and uncertainties are further described in reports filed by SEALSQ with the SEC.

SEALSQ Corp is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

SEALSQ Corp. Carlos Moreira Chairman & CEO Tel: +41 22 594 3000 [email protected]

SEALSQ Investor Relations (US) The Equity Group Inc. Lena Cati Tel: +1 212 836-9611 [email protected]

PHILADELPHIA, Jan. 26, 2026 (GLOBE NEWSWIRE) —

CoreWeave, Inc. (NASDAQ: CRWV) 

WHAT IS HAPPENING? Grabar Law Office is investigating claims on behalf of shareholders of CoreWeave, Inc. (NASDAQ: CRWV). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

If you purchased
CoreWeave, Inc.
(NASDAQ: CRWV)
,
on or near the Company’s March 28, 2025 IPO, and still hold shares today,
you are encouraged to visit

https://grabarlaw.com/the-latest/coreweave-shareholder-investigation/

,
contact Joshua Grabar at

[email protected]

,
or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever.   Alternatively, if you purchased shares between March 28, 2025 and December
15, 2025, you can participate in the underlying class action.

WHY? As alleged in an underlying securities fraud class action complaint, CoreWeave, Inc. (NASDAQ: CRWV), via certain of its officers, made materially false and misleading statements regarding the Company’s business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Defendants had overstated CoreWeave’s ability to meet customer demand for its service; (ii) Defendants materially understated the scope and severity of the risk that CoreWeave’s reliance on a single third-party data center supplier presented for CoreWeave’s ability to meet customer demand for its services; (iii) the foregoing was reasonably likely to have a material negative impact on the Company’s revenue; (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

WHAT CAN YOU DO NOW?
If you purchased
CoreWeave, Inc.
(NASDAQ: CRWV)
,
on or near the Company’s March 28, 2025 IPO, and still hold shares today,
you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit

https://grabarlaw.com/the-latest/coreweave-shareholder-investigation/

,
contact Joshua Grabar at

[email protected]

,
or call 267-507-6085. Alternatively, if you purchased shares between March 28, 2025 and December 15, 2025, you can participate in the class action.

#CoreWeave #CRWV $CRWV

Ibotta, Inc. (NYSE: IBTA):

WHAT IS HAPPENING? Grabar Law Office is investigating claims on behalf of shareholders of Ibotta, Inc. (NYSE: IBTA). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

If you purchased Ibotta, Inc. shares on or shortly after the company’s April 18
, 2024 IPO,
and still hold shares today,
you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit

https://grabarlaw.com/the-latest/ibotta-shareholder-investigation/

, contact Joshua Grabar at

[email protected]

,
or call 267-507-6085, to learn more.

WHY? A federal securities fraud class action complaint alleges that statements made in Ibotta Inc’s (NYSE: IBTA) Registration Statement issued in connection with Ibotta’s April 18, 2024 initial public offering were false and/or misleading when made because they did not properly warn investors of the risks concerning Ibotta’s contract with The Kroger Co. Kroger’s contract was at-will, and Ibotta failed to warn investors that a large client could cancel their contract with Ibotta without warning. Despite providing a detailed explanation of the terms of Ibotta’s contract with Walmart, there was not a single warning of the at-will nature of Kroger’s contract.

WHAT CAN YOU DO NOW?
If you purchased Ibotta, Inc. (NYSE: IBTA) shares on or shortly after the company’s April 18
, 2024 IPO,
and still hold shares today,
you are encouraged to visit

https://grabarlaw.com/the-latest/ibotta-shareholder-investigation/

, contact Joshua Grabar at

[email protected]

,
or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever.   $IBTA #IBTA #Ibotta

Integer Holdings Corp. (NYSE: ITGR):

WHAT IS HAPPENING? Grabar Law Office is investigating claims on behalf of shareholders of Integer Holdings Corp. (NYSE: ITGR). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

If you purchased
Integer Holdings Corp. (NYSE: ITGR),
shares prior to July 25, 2024
,
and still hold shares today,
you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. You are encouraged to visit

https://grabarlaw.com/the-latest/integer-shareholder-investigation/

, contact Joshua Grabar at

[email protected]

,
or call 267-507-6085.

WHY? As alleged in a recently filed federal securities fraud class action complaint, Integer Holdings Corp. (NYSE: ITGR), through certain of its officers, made materially false and/or misleading and failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, it is alleged that the Company failed to disclose that: (1) Integer materially overstated its competitive position within the growing EP manufacturing market; (2) despite Integer’s claims of strong visibility into customer demand, the Company was experiencing a sustained deterioration in sales relating to two of its EP devices; (3) in turn, Integer mischaracterized its EP devices as a long-term growth driver for the Company’s C&V segment; and (4) as a result of the above, Defendants’ positive statements about the Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

WHAT CAN YOU DO NOW?
If you purchased
Integer Holdings Corp. (NYSE: ITGR),
shares prior to July 25, 2024
,
and still hold shares today,
you are encouraged to visit

https://grabarlaw.com/the-latest/integer-shareholder-investigation/

, contact Joshua Grabar at

[email protected]

,
or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. #ITGR $ITGR #IntegerHoldings

Varonis Systems, Inc.


(NASDAQ: VRNS):

WHAT IS HAPPENING? Grabar Law Office is investigating claims on behalf of shareholders of Varonis Systems, Inc. (NASDAQ: VRNS). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

If you purchased
Varonis Systems, Inc.
(NASDAQ: VRNS)
,
prior to
February 4, 2025
, and still hold shares today,
you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. You are encouraged to visit

https://grabarlaw.com/the-latest/varonis-shareholder-investigation/

,
contact Joshua Grabar at

[email protected]

,
or call 267-507-6085. Alternatively, if you purchased shares between February 4, 2025, and October 28, 2025, you can participate in the class action.

WHY? As alleged in an underlying securities fraud class action complaint, Varonis Systems, Inc. (NASDAQ: VRNS), through certain of its officers, provided investors with materially false or misleading information concerning Varonis’ expected annual recurring revenue (“ARR”) for the fiscal year 2025. Defendants’ statements included, among other things, confidence in the Company’s ability to maintain ARR projections while converting both its federal and non-federal existing on-prem customers to the software-asa-service (“SaaS”) alternative offering. Such statements were made while failing to disclose material adverse facts concerning the true state of Varonis’ ability to convert its existing customer base; notably, that it was not truly equipped to convince existing users of the benefits of converting to the SaaS offering or otherwise maintain those customers on its platform, resulting in significantly reduced ARR growth potential in the near-term. When Varonis announced its financial results for the third quarter of fiscal 2025, disclosing a significant miss to ARR and reducing its projections for the full fiscal year 2025, the stock suffered a massive single-day decline of over 48%.

WHAT CAN YOU DO NOW?
If you purchased
Varonis Systems, Inc.
(NASDAQ: VRNS)
,
prior to
February 4, 2025
, and still hold shares today,
you are encouraged to visit

https://grabarlaw.com/the-latest/varonis-shareholder-investigation/

,
contact Joshua Grabar at

[email protected]

,
or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Alternatively, if you purchased shares between February 4, 2025, and October 28, 2025, you can participate in the class action.
#Varonis #VRNS $VRNS

WHY GRABAR LAW OFFICE?

Grabar Law Office is a nationally recognized firm with extensive experience as counsel in complex commercial litigation in state and federal courts throughout the nation, having an emphasis in securities class action and individual shareholder litigation under federal and state securities laws, antitrust litigation under federal and state antitrust laws, and consumer rights under state consumer protection laws. The firm represents and is trusted by numerous publicly listed corporations, multinational manufacturers and distributors, municipalities, universities, business owners and individuals. The firm’s lawyers have been recognized as “AV Preeminent” – peer rated for highest level of professional excellence and ethical standing by Martindale-Hubble, and by Thompson Reuters’ Super Lawyers publication.

Want more information about Grabar Law Office and its attorneys? Please visit: https://grabarlaw.com or contact the firm’s founder, Joshua Grabar directly at [email protected].

Attorney Advertising Disclaimer

Contact:
Joshua H. Grabar, Esq.
Grabar Law Office
One Liberty Place
1650 Market Street, Suite 3600
Philadelphia, PA 19103
Tel:  267-507-6085
Email: [email protected]